1. Jojima, T. et al. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8, 45, https://doi.org/10.1186/s13098-016-0169-x (2016).
2. Seko, Y. et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes 11, 835–843, https://doi.org/10.2147/DMSO.S184767 (2018).
3. Shiba, K. et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 8, 2362, https://doi.org/10.1038/s41598-018-19658-7 (2018)
4. Deacon, C. F., Carr, R. D. & Holst, J. J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci. 13, 1780–1794 (2008).
5. Dicembrini, I., Monami, M. & Mannucci, E. Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge. Nutr Metab Cardiovasc Dis. 29, 215–219, https://doi.org/10.1016/j.numecd.2018.12.009 (2019).
6. Nakamura, K. et al. A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. Int. J. Mol. Med. 39, 969–983, https://doi.org/10.3892/ijmm.2017.2899 (2017).
7. Rohrborn, D., Wronkowitz, N. & Eckel, J. DPP4 in Diabetes. Front Immunol 6, 386, https://doi.org/10.3389/fimmu.2015.00386 (2015).
8. Miyazaki, M. et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol. Med. Rep. 5, 729–733, https://doi.org/10.3892/mmr.2011.707 (2012).
9. Farrell, G. et al. Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology 69, 2241–2257, https://doi.org/10.1002/hep.30333 (2019).
10. Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol 179, 2454–2463, https://doi.org/10.1016/j.ajpath.2011.07.014 (2011).
11. Itoh, M. et al. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2, https://doi.org/10.1172/jci.insight.92902 (2017).
12. Itoh, M. et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, https://doi.org/10.1371/journal.pone.0082163 (2013).
13. Aroor, A. R. et al. Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64, 1988–2001, https://doi.org/10.2337/db14-0804 (2015).
14. Choi, S. H. et al. Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice. Can J. Physiol. Pharmacol 95, 129–139, https://doi.org/10.1139/cjpp-2016-0026 (2017).
15. Tanaka, M. et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat Commun 5, 4982, https://doi.org/10.1038/ncomms5982 (2014).
16. Ghorpade, D. S. et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555, 673–677, https://doi.org/10.1038/nature26138 (2018).
17. Zhuge, F. et al. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization. Diabetes 65, 2966–2979, https://doi.org/10.2337/db16-0317 (2016).
18. Csak, T. et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J. Physiol. Gastrointest Liver Physiol 300, G433–441, https://doi.org/10.1152/ajpgi.00163.2009 (2011).
19. Ye, D. et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 61, 1058–1067, https://doi.org/10.1136/gutjnl-2011-300269 (2012).
20. Iwasaki, Y. et al. Activating transcription factor 4 links metabolic stress to interleukin-6 expression in macrophages. Diabetes 63, 152–161, https://doi.org/10.2337/db13-0757 (2014).
21. Bannasch, P., Enzmann, H., Klimek, F., Weber, E. & Zerban, H. Significance of sequential cellular changes inside and outside foci of altered hepatocytes during hepatocarcinogenesis. Toxicol Pathol 17, 617–628; discussion 629, https://doi.org/10.1177/0192623389017004107 (1989).
22. Cast, A. et al. C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Hepatology 67, 1857–1871, https://doi.org/10.1002/hep.29677 (2018).
23. Snyder, H. S. et al. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J. Clin. Transl. Hepatol. 6, 168–174, https://doi.org/10.14218/JCTH.2017.00050 (2018).
24. Aso, Y. et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl. Res. 159, 25–31, https://doi.org/10.1016/j.trsl.2011.09.005 (2012).
25. Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038–1048, https://doi.org/10.1016/j.metabol.2015.12.012 (2016).
26. Salim, H. M. et al. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. Vascul Pharmacol 96–98, 19–25, https://doi.org/10.1016/j.vph.2017.03.003 (2017).
27. Lee, Y. S. et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55, 2456–2468, https://doi.org/10.1007/s00125-012-2592-3 (2012).
28. He, L. et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J Diabetes Investig 4, 382–392, https://doi.org/10.1111/jdi.12063 (2013).
29. Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347–2355, https://doi.org/10.1194/jlr.M500294-JLR200 (2005).
30. Varin, E. M. et al. Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. Cell Metab. 29, 320–334 e325, https://doi.org/10.1016/j.cmet.2018.10.001 (2019).
31. Giovannucci, E. et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 60, 207–221, https://doi.org/10.3322/caac.20078 (2010).
32. Angulo, P. et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149, 389–397 e310, https://doi.org/10.1053/j.gastro.2015.04.043 (2015).
33. Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554, https://doi.org/10.1002/hep.27368 (2015).
34. Vilar-Gomez, E. et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology 155, 443–457 e417, https://doi.org/10.1053/j.gastro.2018.04.034 (2018).
35. Nishina, S. et al. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. Cell Mol Gastroenterol Hepatol 7, 115–134, https://doi.org/10.1016/j.jcmgh.2018.08.008 (2019).
36. Hollande, C. et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat. Immunol. 20, 257–264, https://doi.org/10.1038/s41590-019-0321-5 (2019).
37. Balthasar, N. et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493–505, https://doi.org/10.1016/j.cell.2005.08.035 (2005).
38. Nakaya, K. et al. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Metabolism 62, 939–951, https://doi.org/10.1016/j.metabol.2013.01.010 (2013).
39. Yamashita, S. et al. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice. Eur. J. Pharmacol 859, 172521, https://doi.org/10.1016/j.ejphar.2019.172521 (2019).
40. Juluri, R. et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J. Clin. Gastroenterol 45, 55–58, https://doi.org/10.1097/MCG.0b013e3181dd1348 (2011).
41. Goto, T. et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci. Rep. 8, 8157, https://doi.org/10.1038/s41598-018-26383-8 (2018).
42. Suganami, T., Nishida, J. & Ogawa, Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α. Arterioscler Thromb Vasc Biol 25, 2062–2068 (2005).
...